Shahar Tzafrir
Managing Partner @ TLV Partners
Shahar Tzafrir is a Series A investor at TLV Partners focused on Software and Artificial Intelligence. Shahar is a Managing Partner at TLV Partners, investing in the idea/seed stage. Over the past decade, he has focused on the intersection of AI as it addresses commercial problems across sectors, including Developer Tools, Biotech, Cloud Native, Construction, Customer Retention, Data Centers, Drug Discovery, Enterprise Software, Health Care,and Taxes.His investment portfolio at TLV Partners includes Buildots, Bond (acquired by Reef), Canopy Immuno-Therapeutics, Covver, Churney, Deepcure, EverAfterAI, Gelt, Granulate (acquired by Intel), Guesty (exit via secondary), Immunai, Odo (acquired by Checkpoint), ScyllaDB, Solvo, Silverfort, and Unleash. He also serves as a Board Observer at Aidoc on behalf of the founders.Before joining TLV Partners, Shahar was a General Partner at Magma Venture Partners, working with funds III and IV. His investment portfolio included Aidoc, Applitools (acquired by Thoma Bravo), Cloudendure (acquired by Amazon), Coretigo, Guesty (exit via secondary), Indegy (acquired by Tenable), ScyllaDB, Syte, Teridion, and Tonkean.Before his venture capital career, Shahar spent 15 years across three startups: Federation (acquired by Cordys), Oblicore (acquired by CA), and DigitalFuel (acquired by VMWare).He served as a software programmer in Israel’s Defense Forces for six years, earning three annual distinction awards at the Unit, Division, and Corps levels.He holds an LL.B., graduating Summa Cum Laude as the Valedictorian. Outside work, he is an amateur nature photographer and a chess player interested in Advanced Chess, a blend of AI and human strategy.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 48%
Last updated:
For AI agents: llms.txt
Industries Shahar Tzafrir invests in
Stages Shahar Tzafrir invests in
Countries Shahar Tzafrir invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $3M–$5.5M
- Series A
- $3M–$40M
- Series B
- $20M–$30M
Investment Focus
Industry
- Software 4 (19%)
- Artificial Intelligence 4 (19%)
- Biotechnology 3 (14%)
- Machine Learning 2 (10%)
- Enterprise Software 2 (10%)
Stage
- Series A 7 (33%)
- Seed 5 (24%)
- Series B 3 (14%)
- Series C 3 (14%)
- Series D 1 (5%)
Country
- Israel 5 (24%)
- United States 5 (24%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Scala Biodesign
|
Scala Biodesign offers partners a one-of-a-kind computational solution to drastically boost the value of proteins and accelerate their development into commercial products. | $16M / Series A / Mar 31, 2026 | |
Converge Bio
|
Converge Bio integrates Generative AI with biological data. Converge Bio mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages. | $25M / Series A / Jan 13, 2026 | |
Gelt
|
Gelt is a software company that offers technology solutions for managing business tax balances, retirement accounts, and other assets. | $13M / Series A / Sep 12, 2025 | |
Buildots
|
Buildots specializes in transforming construction sites into a data-driven digital environment. Its platform enables maximum control of construction processes at minimal effort. The solution turns every site walk into valuable process data that can immediately be used for gaining full control of a certain project. | $45M / Series D / May 29, 2025 | |
|
Converge Bio
|
Converge Bio integrates Generative AI with biological data. Converge Bio mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages. | $5.5M / Seed / Nov 20, 2024 | |
|
Scala Biodesign
|
Scala Biodesign offers partners a one-of-a-kind computational solution to drastically boost the value of proteins and accelerate their development into commercial products. | $5.5M / Seed / Sep 11, 2023 | |
|
Buildots
|
Buildots specializes in transforming construction sites into a data-driven digital environment. Its platform enables maximum control of construction processes at minimal effort. The solution turns every site walk into valuable process data that can immediately be used for gaining full control of a certain project. | $60M / Series C / May 17, 2022 | |
DeepCure
|
DeepCuris builds an AI engine for small-molecule drug discovery. | $40M / Series A / Nov 08, 2021 | |
|
Buildots
|
Buildots specializes in transforming construction sites into a data-driven digital environment. Its platform enables maximum control of construction processes at minimal effort. The solution turns every site walk into valuable process data that can immediately be used for gaining full control of a certain project. | $30M / Series B / Aug 04, 2021 | |
Solvo
|
Solvo allows developers and DevOps to deliver a cloud product with a lease-privileged security configuration. The company's platform creates a customized security configuration for the cloud environment, allowing the R&D and Ops teams to have a secured infrastructure. Solvo was co-founded by Shira Shamban and David Hendri. | $3M / Seed / Oct 07, 2020 | |
| See all 21 investments → | |||
Co-Investors
About TLV Partners
TLV Partners is an early-stage venture capital firm investing in Israeli entrepreneurs who are pushing the boundaries of what is possible. With over $1 billion in assets under management, we invest in untapped markets and wherever breakthrough technologies may be found, including Cybersecurity, Data, AI, DevTools, Fintech, Biotech, eCommerce, andmore. Driven by a passion for innovation, our team partners with the most exceptional founders and empowers them to transform their disruptive ideas into successful, category-defining companies. Since 2015, the firm has backed Israel's most promising companies, including Aqua Security, Next Insurance, Unit, Firebolt, Immunai, Granulate (acquired by Intel), Puresec (acquired by Palo Alto Networks), Oribi (acquired by LinkedIn), Neosec (acquired by Akamai), and more. For more information visit www.tlv.partners.
TLV Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adi Yarel-Toledano
Partner-CFO
|
|||
Brian Sack
Principal
|
|||
Dana Harel
Head of Marketing
|
|||
Eitan Bek
Co-Founder & Managing Partner
|
|||
Rona Segev
Co-Founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Shahar Tzafrir invest in?
Shahar Tzafrir invests primarily in Software, Artificial Intelligence and Biotechnology startups, most often at Series A and Seed stage. Most of the 21 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shahar Tzafrir's check size?
Shahar Tzafrir typically joins rounds of $3M–$5.5M at Seed, $3M–$40M at Series A and $20M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shahar Tzafrir participates in.
How do I contact Shahar Tzafrir?
Public channels for Shahar Tzafrir include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Shahar Tzafrir last invest?
The most recent investment recorded for Shahar Tzafrir closed in Mar 2026. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
